ALVIO.PA down 6.91% on 06 Jan 2026 after hours: 50-day avg €0.142 signals watchlist
ALVIO.PA stock fell sharply in after-hours trade on 06 Jan 2026, closing at €0.155, down 6.91% on the session. The move made Valerio Therapeutics SA (ALVIO.PA) one of the top losers on EURONEXT as volume reached 1,047,836 shares. We examine the near-term drivers behind the drop, the company’s liquidity profile, and what technicals and our models say about a realistic price path.
ALVIO.PA stock: after-hours price action and market context
Valerio Therapeutics SA (ALVIO.PA) traded at €0.155 in after-hours on 06 Jan 2026, down €0.0115 from the previous close of €0.1665. Intraday range was €0.148–€0.168 and volume hit 1,047,836, below the 30-day average of 1,698,576 shares.
The move placed ALVIO.PA among the session’s top losers on EURONEXT. The broader Healthcare sector in Europe showed mild weakness today, which amplified pressure on smaller biotechnology names with limited liquidity.
Drivers behind the decline and news flow
There is no single public company announcement tied to today’s after-hours drop. Market participants pointed to mixed analyst commentary and sector rotation away from small-cap biotech as catalysts. Recent headlines listed ALVIO.PA among smaller biotech movers on Yahoo Finance and related feeds source and source.
Near-term calendar risk remains material: Valerio’s next earnings or clinical update timeline includes an earnings announcement scheduled for 2026-02-25. With clinical-stage assets such as AsiDNA in Phase 1, any trial update or funding news could quickly swing the stock.
ALVIO.PA stock: financials and valuation snapshot
Valerio Therapeutics reports EPS of -0.09 and a negative PE of -1.72, reflecting ongoing losses at the clinical stage. Market cap stands near €54,196,508 with 349,654,888 shares outstanding. Revenue per share is €0.01 and R&D represents 64.43% of revenue, underlining high development spend.
Liquidity metrics are a concern: cash per share is €0.017 and current ratio is 0.35, indicating limited short-term coverage. Price-to-sales is 31.81, and EV/Revenue is elevated at 40.52, which signals the market is pricing recovery and clinical success into the stock.
Technicals and sentiment for ALVIO.PA stock
Short-term technicals show weakness: RSI is 33.98, the stock is near the lower Bollinger Band (lower €0.10), and MACD histogram is negative. The 50-day average sits at €0.142 and the 200-day average at €0.082, so the current price €0.155 is above the 50-day but well above the longer-term trend line.
Volume trend shows below-average trade today, and momentum indicators (CCI -115.67, Stochastic %K 2.04) point to oversold conditions. These readings suggest high intraday volatility and quick mean-reversion risk on any clinical or licensing update.
Meyka AI rating and ALVIO.PA stock forecast
Meyka AI rates ALVIO.PA with a score out of 100: 69.57 (Grade B) — Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.
Meyka AI’s forecast model projects a monthly price of €0.13, a yearly price of €0.1235, and a 3-year target of €0.1704. Against the current price €0.155, the model implies a -16.13% move to the monthly forecast and a -20.35% move to the yearly forecast. Forecasts are model-based projections and not guarantees.
Outlook, price targets and risk factors for ALVIO.PA stock
Realistic near-term price targets reflect model output and clinical risk: a conservative short-term target is €0.12, a medium-term target is €0.17, and a bull-case 3–5 year target is €0.22, tied to successful clinical readouts or new licensing deals. These targets assume no large equity dilution and steady R&D progress.
Key risks include cash runway constraints, trial setbacks, and low liquidity on EURONEXT. Catalysts to watch are clinical updates for AsiDNA, any partnership announcements, and the fiscal update around 2026-02-25. For more data and live signals see Meyka AI’s stock page Meyka ALVIO.PA.
Final Thoughts
ALVIO.PA stock closed after hours on 06 Jan 2026 at €0.155, down 6.91%, marking it among the session’s top losers on EURONEXT. Fundamentals show a clinical-stage biotech with heavy R&D spend, EPS -0.09, constrained liquidity (cash per share €0.017, current ratio 0.35) and high valuation multiples versus revenue. Technicals point to oversold short-term conditions but continued volatility. Meyka AI’s forecast model projects a yearly price near €0.1235, implying roughly -20.35% from today’s level, while a 3-year horizon shows upside to €0.1704 if clinical progress materializes. Given the mixed signals, Meyka AI’s grade is B — HOLD, reflecting balanced upside potential against material execution and funding risks. Traders should monitor trial news, the 2026-02-25 announcement, and any liquidity events before adjusting positions.
FAQs
There was no single company release; the drop reflects sector rotation in biotech, mixed analyst attention and pre-earnings caution ahead of a **2026-02-25** announcement.
Meyka AI rates ALVIO.PA **69.57/100 (Grade B — HOLD)** and models a yearly price of **€0.1235**, implying about **-20.35%** versus today. Forecasts are projections, not guarantees.
Watch short-term target **€0.12**, medium **€0.17**, and a bull-case **€0.22**. Main risks are cash runway, trial setbacks for AsiDNA, dilution, and low liquidity on EURONEXT.
Disclaimer:
Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.
